E.g., 02/24/2020
E.g., 02/24/2020

bioMérieux receives FDA 510(k) clearance for VIDAS® 3, the new generation of VIDAS®

27 July, 2015

Innovative VIDAS® immunoassays system designed to answer clinical laboratories needs for automation, traceability, quality and optimized workflow

Global experts engage in the fight against antimicrobial resistance during the World HAI/Resistance Forum organized by bioMérieux

22 June, 2015

For the Forum’s 5th edition, bioMérieux commits to support a global educational project on the fight against antimicrobial resistance recognized as a major global public health threat.

Strategic alliance between bioMérieux and COPAN to automate clinical microbiology laboratories and enhance their operational efficiency

09 January, 2015

bioMérieux distributes COPAN’s WASP® and WASPLab™ automated systems and speeds up deployment of its “FMLA® - Lab Efficiency” vision 

bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections

18 November, 2014

Marcy l’Etoile, France – San Diego, California, United States – November 18, 2014 – bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina, a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. The two companies will jointly develop applications for microbiology sequencing technologies within a four-year renewable period.

BioFire Defense, a bioMérieux company, receives fast-track authorization of FilmArray® Ebola Test

27 October, 2014

Marcy l’Etoile (France) - October 27, 2014 - BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its commercial FilmArray® Ebola test (BioThreat-E test™).

bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked

23 July, 2014

Marcy l'Etoile, France, July 23, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIRTUO™, the new generation of BacT/ALERT®, has been CE-marked. This uniquely innovative automated blood culture microbial detection system further enriches the offering of the BacT/ALERT® product range and is now commercially available in targeted countries that recognize CE marking. The enhanced performance of the system will help laboratories provide rapid results to clinicians to help maximize laboratory efficiency and facilitate better patient outcomes.

Pioneering diagnostics